Document Analysis NLP IA
FREQ, RAKE or TFIDF
Summary (IA Generated)
Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design.
The startup creates computer-designed, virus-like particles that are used in vaccines to trigger immune responses.
The new funding follows a $51 million round in October 2019.
“Based on preclinical data, we believe our vaccine candidates could offer significant protection against leading viral causes of pneumonia in older adults where no licensed vaccines currently exist,” said Icosavax CEO Adam Simpson, regarding the RSV and hMPV vaccines.
The company launched its COVID program in October, supported in part by $10 million from the Bill & Melinda Gates Foundation.
Strong ties to the Institute for Protein Design: The company is a spinout from the University of Washington’s Institute for Protein Design (IPD).